{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gout/prescribing-information/febuxostat/","result":{"pageContext":{"chapter":{"id":"9830ccbd-f551-5585-a69a-4674759f70cd","slug":"febuxostat","fullItemName":"Febuxostat","depth":2,"htmlHeader":"<!-- begin field f8220700-c9e8-42ed-97b1-2eeaf74f0224 --><h2>Febuxostat</h2><!-- end field f8220700-c9e8-42ed-97b1-2eeaf74f0224 -->","summary":"","htmlStringContent":"<!-- begin item b1d4e026-959a-473e-8622-f8d9009503c2 --><!-- end item b1d4e026-959a-473e-8622-f8d9009503c2 -->","topic":{"id":"7ec7842e-cb8a-5712-bb55-65480a391cb5","topicId":"b578fac4-ab4b-4d7b-9df9-2136b4d90e75","topicName":"Gout","slug":"gout","lastRevised":"Last revised in February 2018","chapters":[{"id":"2e71494e-f9a3-5368-8903-3d2121329748","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"738bb44e-1a50-5bc5-8df4-83ac66475493","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"69338c48-0d43-5ae0-9591-5ef289880366","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0f7680ff-9a88-520a-b2b5-1ff130dfa69b","slug":"changes","fullItemName":"Changes"},{"id":"ae66c6f1-78f9-5532-b310-9d6957882c0c","slug":"update","fullItemName":"Update"}]},{"id":"5de6e4cf-e0c8-56e2-a357-3d063b324cd0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"86664a1d-e3e5-58c9-957b-56affa17f103","slug":"goals","fullItemName":"Goals"},{"id":"39593d8e-f904-5b99-80e9-e619caf1ec37","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca59f248-a0b2-5f6c-bfcf-2333dc94f1d9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"57ca55f4-826e-5832-85a7-dd89f3486be2","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"621c09b7-b5e8-593b-aeb2-fc4a86b884c8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b39fbed2-7c0d-5440-a769-bab311a7b4d2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"362edeaf-2f90-506d-b203-f5dbbbfb5835","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a8de4056-6ec0-59ff-911b-561bf7fdb32d","slug":"definition","fullItemName":"Definition"},{"id":"45a8241d-2a2d-5a48-a6d6-2b5ebe02ec27","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"92d229bf-8656-5cfa-aecc-9c069389300f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"79d3b1c2-8d49-55be-99af-41b37c84d582","slug":"complications","fullItemName":"Complications"},{"id":"27dd91cd-92bb-5c2d-8fe8-a184bffce6e7","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ca0e383b-327b-58c2-adb4-6c5081b6fd8e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ddea0193-0c14-53db-8e1e-2e71f514988e","slug":"assessment","fullItemName":"Assessment"},{"id":"5a86623b-b32c-5e12-b9fe-b1b5a1f7e58f","slug":"investigations","fullItemName":"Investigations"},{"id":"42a5d4a2-b908-5027-8fb8-f5f336db4c7e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5a915955-8e0e-54ae-a1cc-f5875d84d2a2","fullItemName":"Management","slug":"management","subChapters":[{"id":"8a8b4d2a-4efb-5bef-9780-70dc540d41bd","slug":"acute-gout","fullItemName":"Scenario: Acute gout"},{"id":"98793041-11dd-5159-a376-82f5440ee713","slug":"preventing-gout","fullItemName":"Scenario: Preventing gout"}]},{"id":"050e571e-a7a5-5659-9790-2daf0b56580a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e7cfef3f-4ab1-5d17-8300-30e91a70eb96","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"cadf7df3-5301-560b-a8ff-e85cfee9ba7c","slug":"colchicine","fullItemName":"Colchicine"},{"id":"60f4beab-f8fc-50e5-8ed9-5073dd8533ec","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"2d2fee49-9ad0-5f0a-9ef1-f253794ed2c7","slug":"allopurinol","fullItemName":"Allopurinol"},{"id":"9830ccbd-f551-5585-a69a-4674759f70cd","slug":"febuxostat","fullItemName":"Febuxostat"},{"id":"ff3edf82-1b21-591c-a8a5-a3b40e7386a5","slug":"paracetamol","fullItemName":"Paracetamol"}]},{"id":"776d98f0-f8da-57c2-983e-1291ac67b761","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"71a86333-9110-5847-a2c2-eabf7903c269","slug":"application-of-an-ice-pack","fullItemName":"Application of an ice pack"},{"id":"25688946-80c0-52ab-a32d-99ccab4d738c","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"2921e0f0-467f-5231-87d0-9fed766653ee","slug":"oral-colchicine","fullItemName":"Oral colchicine"},{"id":"09bbf9d4-fe62-5ae1-bc49-f2fede12f711","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"409d2bc0-16d2-5104-8857-eeb5db2a1ecc","slug":"dietary-measures","fullItemName":"Dietary measures"},{"id":"08526f72-ca5a-50db-94b6-3380365360fd","slug":"colchicine-to-prevent-recurrent-gout","fullItemName":"Colchicine to prevent recurrent gout"},{"id":"a53517a7-6d7e-5d2f-886d-e2a3f1bc27b1","slug":"urate-lowering-drugs-in-prevention","fullItemName":"Urate-lowering drugs in prevention"}]},{"id":"f83d98a9-6ce1-50d4-92ad-dd354662a444","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"568c43a6-b0d8-546e-84d2-45781ce305cc","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5b7cac11-c21d-59fc-83d9-bf16d0d3ab0b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0e4d0013-b7bc-5179-ac55-8104dec2762c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d75afbe0-7c3d-504e-b369-e56eac297bad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"45249d1d-8c92-5402-b4f3-108a8a39d94f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"44f1a411-2cf4-55e8-b5e8-266cd568655e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"050e571e-a7a5-5659-9790-2daf0b56580a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"333729e5-1922-575a-a541-0f1c91791aee","slug":"prescribing-febuxostat","fullItemName":"Prescribing febuxostat","depth":3,"htmlHeader":"<!-- begin field fef1652b-8e4c-449a-bdab-ef58ff4c0073 --><h3>How should I prescribe febuxostat?</h3><!-- end field fef1652b-8e4c-449a-bdab-ef58ff4c0073 -->","summary":"","htmlStringContent":"<!-- begin item e4fb18cf-38e4-4695-8249-ae27f9b3f26e --><!-- begin field 583036f9-aa20-4808-8695-540ae3041e6d --><ul><li>Consider febuxostat as an alternative second-line therapy if allopurinol is not tolerated or is contraindicated (for example if renal impairment prevents adequate allopurinol dose increases).<ul><li>Prescribers should be aware that a prior history of hypersensitivity to allopurinol and/or renal disease may indicate potential hypersensitivity to febuxostat.</li></ul></li><li>Start febuxostat after the acute attack has resolved.</li><li>Perform liver function tests (LFTs) before starting febuxostat treatment, as mild liver test abnormalities have been observed. Check LFTs periodically thereafter, based on clinical judgement.</li><li>Prescribe febuxostat at a starting dose of 80 mg once daily. If the serum uric acid (SUA) level is greater than 300 micromol/L after 4 weeks, increase the dose of febuxostat to 120 mg once daily, aiming for a therapeutic target SUA level of below 300 micromol/L. <ul><li>In people with mild hepatic impairment, a maximum dose of 80 mg daily is recommended. There is limited information regarding the use of febuxostat in people with more severe hepatic impairment.</li><li>No dose adjustment is needed for the elderly, or those with mild or moderate renal impairment. Febuxostat has not been fully evaluated in people with severe renal impairment (creatinine clearance less than 30 ml/min).</li></ul></li><li>When starting or up-titrating febuxostat, flare prophylaxis using <a class=\"topic-reference internal-reference\" href=\"/topics/gout/prescribing-information/colchicine/\">colchicine</a> or an NSAID is recommended - see <a class=\"topic-reference internal-reference\" href=\"/topics/gout/management/preventing-gout/#drug-treatment\">Gout prevention</a> section.</li><li>If a gout flare occurs during treatment with febuxostat:<ul><li>Advise that febuxostat should <em>not </em>be discontinued.</li><li>Manage the flare as appropriate for the person.</li><li>Reassure the person that continuous treatment with febuxostat will decrease the frequency and intensity of further gout flares.</li></ul></li><li>Avoid febuxostat in people with ischaemic heart disease or heart failure.</li><li>Information on prescribing febuxostat is based mainly on a guideline produced by expert representatives of the British Society for Rheumatology (BSR) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Hui, 2017</a>], the Technology Appraisal: <em>Febuxostat for the management of hyperuricaemia in people with gout, </em>published by the National Institute for Health and Clinical Excellence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">NICE, 2008b</a>] and the Summary of Product Characteristics for Adenuric<sup>® </sup>film-coated tablets [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">ABPI, 2017</a>].<ul><li>The BSR recommend The Summary of Product Characteristics for Adenuric<sup>® </sup>film-coated tablets and the British National Formulary recommend that a prophylactic nonsteroidal anti-inflammatory drug (NSAID) or colchicine is co-prescribed for at least 6 months when starting febuxostat [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">BNF 74, 2017</a>].<ul><li>The BSR advises that prophylaxis with colchicine can be given for up to 6 months [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Hui, 2017</a>].</li></ul></li></ul></li><li><strong>Hepatic impairment</strong><ul><li>The manufacturers recommend that a maximum dose of 80 mg once daily is prescribed to people with mild hepatic impairment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">ABPI, 2017</a>].</li></ul></li></ul><!-- end field 583036f9-aa20-4808-8695-540ae3041e6d --><!-- end item e4fb18cf-38e4-4695-8249-ae27f9b3f26e -->","subChapters":[]},{"id":"e2c23c66-b097-5899-92c9-55f56c3eb121","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 62cbe0d4-020c-474f-827d-3aa69129eff2 --><h3>How should I manage the adverse effects of febuxostat?</h3><!-- end field 62cbe0d4-020c-474f-827d-3aa69129eff2 -->","summary":"","htmlStringContent":"<!-- begin item fb359aab-df43-4d23-8eeb-b86c5e39b3bc --><!-- begin field 4ba180b5-6df1-4b43-8e7e-adee17267d4d --><ul><li>There is a risk of precipitating acute attacks of gout after starting febuxostat.<ul><li>Advise people who experience acute attacks of gout after initiation of treatment with febuxostat, or during established treatment, to continue taking febuxostat.</li></ul></li><li>The most commonly reported adverse effects in clinical trials of febuxostat have been mostly mild or moderate in severity. The most common adverse effects are liver abnormalities, diarrhoea, headache, nausea, and rash.</li><li>There have been post-marketing reports of rare serious rashes, generalised skin rashes, and severe hypersensitivity reactions occurring mostly during the first month of treatment with febuxostat. Some of the people affected reported previous hypersensitivity to allopurinol. Following on from this, the Medicines and Healthcare products Regulatory Agency have advised that:<ul><li>Febuxostat should be stopped immediately if signs or symptoms of serious hypersensitivity reactions occur; early withdrawal is associated with a better prognosis.</li><li>If a hypersensitivity reaction occurs with febuxostat, including Stevens-Johnson syndrome, febuxostat must not be re-started at any time.</li><li>Anyone taking febuxostat should be advised of the signs and symptoms of severe hypersensitivity reactions or Stevens-Johnson syndrome.</li><li>A prior history of hypersensitivity to allopurinol and/or renal disease may indicate potential hypersensitivity to febuxostat.</li></ul></li><li>Somnolence, dizziness, and paresthesia have been reported with febuxostat use.<ul><li>Advise that when starting febuxostat, people should be cautious about driving or using machinery until they are reasonably certain that febuxostat does not adversely affect their performance.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">MHRA, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">ABPI, 2017</a>]</p><!-- end field 4ba180b5-6df1-4b43-8e7e-adee17267d4d --><!-- end item fb359aab-df43-4d23-8eeb-b86c5e39b3bc -->","subChapters":[]},{"id":"1493a357-97b6-51c3-a07e-1a5deab99a0e","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field cf1e6243-fa71-4b86-afd7-a92800878f8f --><h3>Drug interactions</h3><!-- end field cf1e6243-fa71-4b86-afd7-a92800878f8f -->","summary":"","htmlStringContent":"<!-- begin item fce1827e-5b6f-4da9-8e74-a92800878dca --><!-- begin field d18a6ff4-cbe2-4690-a07b-a92800878f8f --><ul><li><strong>Mercaptopurine and azathioprine.</strong> Concomitant use with mercaptopurine or azathioprine is not recommended. The manufacturers SPC details that where this combination cannot be avoided the dose of mercaptopurine/azathioprine should be reduced to 20% or less of the previously prescribed dose.</li><li><strong>Inducers of glucuronidation.</strong> Potent inducers might possibly lead to increased metabolism and decreased efficacy of febuxostat. Monitoring of serum uric acid is therefore recommended 1-2 weeks after start of treatment with a potent inducer of glucuronidation. These drugs include rifampicin, phenytoin and phenobarbitone. Conversely, cessation of treatment of an inducer might lead to increased plasma levels of febuxostat.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">ABPI, 2018b</a>]</p><!-- end field d18a6ff4-cbe2-4690-a07b-a92800878f8f --><!-- end item fce1827e-5b6f-4da9-8e74-a92800878dca -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}